Literature DB >> 9557248

Systemic antibiotics for acne.

J Meynadier1, M Alirezai.   

Abstract

Antibiotic therapy for acne is very common. Antibiotics are frequently used in acne, either systemically or topically. Systemic antibiotics are indicated as treatment of moderate and quite severe acne or if acne is considered as very serious by the patient for psychological or social reasons. Results are very often excellent, but failure is possible; in this case using another treatment, especially isotretinoin, is necessary. A few antibiotics are useful: tetracyclines (tetracycline, doxycycline, minocycline, lymecycline), erythromycin, co-trimoxazole and trimethoprim. Their side effects are reviewed. During pregnancy the best antibiotic is erythromycin. For the nursing mother it is generally said that tetracyclines are contraindicated but the risks if they exist are certainly slight. The mechanism of action of systemic antibiotics for acne is not perfectly clear as it is not only antimicrobial: they diminish chemotaxis of polymorphonuclear leukocytes, modify the complement pathways and inhibit the polymorphonuclear leukocyte chemotactic factor and the lipase production in Propionibacterium acnes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557248     DOI: 10.1159/000017847

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  12 in total

1.  Presumed hypersensitivity to minocycline and conjunctival infiltration.

Authors:  C Parc; A P Brézin; I Nataf; D Dusser; L Moachon; F D'Hermies
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

Review 2.  Acne: more than skin deep.

Authors:  J Ayer; N Burrows
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

3.  Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events.

Authors:  Leisha D Nolen; Rita M Traxler; Grishma A Kharod; Pallavi A Kache; Stefan Katharios-Lanwermeyer; Katherine A Hendricks; Sean V Shadomy; William A Bower; Dana Meaney-Delman; Henry T Walke
Journal:  Health Secur       Date:  2016-11-29

4.  Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

Authors:  R A Lawrenson; H E Seaman; A Sundström; T J Williams; R D Farmer
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

5.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

Review 6.  Current concepts of the pathogenesis of acne: implications for drug treatment.

Authors:  Harald Gollnick
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

Authors:  Aminah Jatoi; Kendrith Rowland; Jeff A Sloan; Howard M Gross; Paul A Fishkin; Stephen P Kahanic; Paul J Novotny; Paul L Schaefer; David B Johnson; Loren K Tschetter; Charles L Loprinzi
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

8.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

9.  Acne vulgaris treatment : the current scenario.

Authors:  Sanjay K Rathi
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

10.  Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.

Authors:  Thomas C Wehler; Claudine Graf; Markus Möhler; Jutta Herzog; Martin R Berger; Ines Gockel; Hauke Lang; Matthias Theobald; Peter R Galle; Carl C Schimanski
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.